Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2006

View Archived Issues

Ostabolin-C safe, active in healthy, older volunteers

Oral gallium superior to intravenous formulation in vitro

Mechanism of PT-100 antitumor activity explored

Antitoxicity, inhibitory effects of As4O6 investigated in vitro

Neuropeptide Y Y1 receptor a potential target for breast cancer treatment

Evaluation of Coenzyme Q10 in Duchenne muscular dystrophy moves to phase III

Positive interim phase II results for CUV-1647 in polymorphous light eruption

Chemokine Therapeutics reacquires CTCE-0214 rights

YM BioSciences to acquire Eximias Pharmaceutical

Athenagen acquires Osprey Pharmaceutical

GSK obtains rights to Japan Tobacco drug in MEK inhibition

Pfizer to acquire rights to fesoterodine for overactive bladder

FermaVir receives FDA advice on development of shingles drug CF-1743

Cortex receives written confirmation on CX-717 clinical hold

Fast track designation for TheraQuest's Tramadol ER

New phase III trial studies Velcade with rituximab in follicular lymphoma

Eprodisate NDA filed and granted priority review for AA amyloidosis

American Pharmaceutical Partners and American BioScience merge

New gamma-secretase inhibitor markedly reduces Abeta levels in vivo

Novel agents for urological disorders disclosed in recent patent literature

Recent patents impart new agents for obesity and lipoprotein disorders

Fast track status for thrombin receptor antagonist SCH-530348

FDA accepts Novartis' Rasilez submission for review

Roche submits BLA for CERA

New anticoagulant agents emerge from sanofi-aventis R&D

Oncolytic adenoviruses plus cytostatic agents as novel approach for prostate cancer

New potent, highly selective Tie-2 kinase inhibitor from Amgen demonstrates in vivo efficacy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...